A Case Series of a Luteolin Formulation (Neuroprotek®) in Children with Autism Spectrum Disorders
-
- T.C. Theoharides
- Laboratory of Molecular Immunopharmacology and Drug Discovery, Department of Molecular Physiology and Pharmacology, Boston, MA, USA
-
- S. Asadi
- Laboratory of Molecular Immunopharmacology and Drug Discovery, Department of Molecular Physiology and Pharmacology, Boston, MA, USA
-
- S. Panagiotidou
- Laboratory of Molecular Immunopharmacology and Drug Discovery, Department of Molecular Physiology and Pharmacology, Boston, MA, USA
書誌事項
- 公開日
- 2012-04
- 権利情報
-
- https://journals.sagepub.com/page/policies/text-and-data-mining-license
- DOI
-
- 10.1177/039463201202500201
- 公開者
- SAGE Publications
この論文をさがす
説明
<jats:p>There has been an impressive, little understood increase in cases of Autism Spectrum Disorders (ASD). The lack of any distinctive pathogenetic mechanism has hampered the development of any effective treatments. Increasing evidence indicates oxidative stress, brain inflammation, gastrointestinal (GI) dysfunction and allergic symptoms may be present in ASD patients. The flavone luteolin has antioxidant, anti-flammatory, anti-allergy and neuroprotective properties. Given these findings, a dietary supplement was developed with a unique mixture of luteolin with the related flavonoids quercetin and rutin in a liposomal formulation of olive kernel oil (OKO), which increases their absorption. Results are presented for children with ASD (n=37, 4–14 years old) who had not obtained any benefit from multiple other regimens and who used this formulation for at least 4 months. GI and allergy symptoms improved in about 75% of children, eye contact and attention in 50%, social interaction in 25% and resumption of speech in about 10%. There were no adverse effects. Even though these results represent an uncontrolled open case series, they are encouraging because they suggest good tolerability and potential effectiveness.</jats:p>
収録刊行物
-
- International Journal of Immunopathology and Pharmacology
-
International Journal of Immunopathology and Pharmacology 25 (2), 317-323, 2012-04
SAGE Publications